Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.1546 | 0.1546 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.014 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.014 | 1 | 1 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0084 | 0.2605 | 0.2605 |
Echinococcus multilocularis | acetylcholinesterase | 0.014 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | RNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.014 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0084 | 0.2605 | 0.5 |
Brugia malayi | Kringle domain containing protein | 0.0084 | 0.2605 | 0.2605 |
Brugia malayi | Protein kinase domain containing protein | 0.0084 | 0.2605 | 0.2605 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Loa Loa (eye worm) | hypothetical protein | 0.0084 | 0.2605 | 0.2605 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0084 | 0.2605 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus multilocularis | carboxylesterase 5A | 0.014 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Schistosoma mansoni | hypothetical protein | 0.0084 | 0.2605 | 0.2605 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0084 | 0.2605 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Mycobacterium ulcerans | hypothetical protein | 0.0065 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus multilocularis | acetylcholinesterase | 0.014 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Leishmania major | hypothetical protein, conserved | 0.0084 | 0.2605 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.014 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.014 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.014 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0084 | 0.2605 | 0.2605 |
Echinococcus granulosus | acetylcholinesterase | 0.014 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0084 | 0.2605 | 0.2605 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.1546 | 0.1546 |
Onchocerca volvulus | 0.0084 | 0.2605 | 1 | |
Toxoplasma gondii | kringle domain-containing protein | 0.0084 | 0.2605 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 167.158 uM | PubChem BioAssay. Luminescence-based cell-based high throughput dose response assay to identify activators of Transthyretin (TTR) transcription. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 55.162 uM | PubChem BioAssay. Counterscreen for activators of Transthyretin (TTR) transcription: Luminescence-based cell-based high throughput dose response assay to identify inhibitors of Transthyretin (TTR) transcription in HuH7 hepatoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.